“While stem cell research is at a very early stage, it appears to offer great promise to quicken the pace of discovery for a cure for diabetes. JDRF encourages the pursuit of this line of research within the framework of appropriate scientific and ethical safeguards established by representatives of the public.” —Sandra Puczynski, Ph.D., Chair of Research JDRF Statement in Support of Stem Cell Research December 8, J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l

JDRF Oversight Committee for Human Stem Cell Research James Hansen, M.D. (Chair) – Emanuel Children’s Diabetes Center, OR Tim Caulfield, LLB, LLM – Health Law Institute, Edmonton Michael DeVita, M.D. – University of Pittsburgh Medical Center Robert Goldman, Ph.D. – Northwestern University School of Medicine Ronald McKay, M.D. – NINDS, National Institutes of Health Margery Perry – JDRF Lay Review Chair Gail Pressberg – Institute for Civil Society, Newton, MA Austin Smith, Ph.D. – University of Edinburgh S. Robert Levine, M.D. – JDRF Lay Review Committee Eric Meslin, Ph.D. – IU Center for Bioethics Charlie Queenan (ex officio) – JDRF Chair of Research

Recommendations of the Stem Cell Oversight Committee March, 2001 JDRF should support: research on the derivation and use of embryonic germ (EG) cells and adult stem cells; research on the derivation and use of embryonic stem (ES) cells derived from excess fertilized eggs after infertility treatment. At present, JDRF should not support research using embryos created solely for research, or embryos created by somatic cell nuclear transfer, but should leave the door open to revisit this matter in future. J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l

Implementation Details January, 2003 There should be clear separation between the decision to create embryos for reproductive purposes and the decision to donate excess embryos for stem cell research. Research consent process should allow for timely, fully informed, and voluntary consent. There should be no financial inducements, monetary or otherwise, for the donation of embryos or gametes for research. The attending fertility physician should make all clinical treatment decisions independent of and uninfluenced by any potential research use of excess embryos. Embryos used for research should not be maintained intact in culture beyond internationally accepted time limits (14 days). J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l

JDRF Partnerships for Stem Cell Research J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l USA Allowed SwedenAllowed Restricted Allowed status Partnership LAUNCHED UK Allowed Discussions CanadaAllowedRecommended Discussions Australia Allowed Restricted Discussions Human Embryonic Germ (hEG) CellsStem (hES) Cells Human Embryonic FinlandAllowed Discussions SingaporeAllowed Discussions

J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l JDRF-funded Stem Cell Projects Human Embryonic Stem Cells (~ US$ 1.4 M in FY2002) Yuichi Hori, M.D., Ph.D., Stanford University Seung Kim, M.D., Ph.D., Stanford University Douglas Melton, Ph.D., Harvard University Jon Odorico, M.D., University of Wisconsin – Madison Andrew Elefanty, Ph.D., and Martin Pera, Ph.D. Monash University, Melbourne, Australia David Hill, Ph.D., Lawson Health Research Institute, Canada Ernest Arenas, Ph.D., Karolinska Institute, Stockholm, Sweden Rolf Ohlsson, Ph.D., Uppsala University, Sweden Lars Arhrlund-Richter, M.D., Ph.D., Karolinska Institute, Stockholm, Sweden Henrik Semb, Ph.D., Goteborg University, Sweden Michael Welsh, Ph.D., Uppsala University, Sweden Shanta Persaud, Ph.D., King’s College London, UK

J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l JDRF-funded Stem Cell Projects Human Fetal Tissue or EG Cells (~ US$ 704,000 in FY2002) Steven Goldman, M.D., Ph.D., Cornell University Medical School Michael Shamblott, Ph.D., Johns Hopkins University Harry Heimberg, Ph.D., Vrije University Brussels, Belgium Raphael Scharfmann, M.D., Ph.D., Inserm, Paris, France Patrik Brundin, Ph.D., Lund University, Sweden Lee Turnpenny, Ph.D., University of Southampton, UK David Wilson, Ph.D., University of Newcastle, UK

J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l JDRF-funded Stem Cell Projects Human Adult Stem Cells (~ US$ 1.1 M in FY2002) Alberto Hayek, M.D., University of California San Diego Catherine Verfaillie, Ph.D., University of Minnesota Sten Erik Jacobsen, Ph.D., Lund University, Sweden Monica Nister, Ph.D., Karolinska Institute, Stockholm, Sweden Mark Dunne, Ph.D., University of Sheffield, UK Animal Stem Cells (~ US$ 480,000 in FY2002) Markus Stoffel, M.D., Ph.D., Rockefeller University Carlos Ibanez, Ph.D., Karolinska Institute, Sweden Stefan Karlsson, M.D., Ph.D., Lund University, Sweden Urban Lendahl, Ph.D., Karolinska Institute, Sweden Patrik Rorsman, Ph.D., Lund University, Sweden Henryk Zulewski, M.D., University of Geneva, Switzerland

Stem cellHow?  cells What we want: To derive new hESC lines useful for therapies. To characterize existing lines and use them to study beta cell development. To make hESC lines freely available to academic researchers. To promote information exchange and research according to the highest ethical standards. J u v e n i l e D i a b e t e s R e s e a r c h F o u n d a t i o n I n t e r n a t i o n a l